Pharmaceutical Executive, Nov 1, 2010

Features

The Fruits of Comparative Effectiveness

By Edward Tuttle , Anita Chawla , Dave Nellesen , Justin Works

New CER tools grant payers the evidence they need to control drug costs

Science and Politics at the FDA

By Walter Armstrong

Harvard professor Daniel Carpenter offers a piercing analysis of the FDA and sheds light on its biggest challenges

The Rx Club

By Jennifer Ringler

The Rx Club Awards have evolved over the years, but the essential 'wow' factor has remained a constant

Columns

Japan: The Real Emerging Market?

By William Looney

With all the money and momentum focused on medicines in emerging markets, it may be time to take a closer look at business opportunities in this more familiar neighbor to the East

Specialty Care Medicines: Managing the Impact of US Health Reform

By John Swen

There's been much talk of how US health reform will impact physicians, patients, and insurance companies. But how will it affect the often overlooked specialty drug market?

Regional Marketing, National Growth

By Jeffrey Spanbauer

Pharm Exec sits down with an expert on regional marketing to ascertain what it takes to drive strong brand results

Lifting the Veil

By Jon Zifferblatt

A shakeout is ahead as China restructures its murky and insular system of drug distribution

Integrating R&D Within M&As

By Rick Heinick

The CEO should be able to communicate the vision of a merger—strategically, financially, operationally, and with the entire organization in mind

Comparisons and Costs

By Jill Wechsler

PCORI is independent and transparent and likely to alter methods for assesssing the value of new therapies